BI 655066 (Risankizumab) Proof of Concept Dose Finding Study in Ankylosing Spondylitis (AS)
Status:
Completed
Trial end date:
2016-07-25
Target enrollment:
Participant gender:
Summary
The overall purpose of the trial is to assess the clinical efficacy of three different
subcutaneous doses of BI 655066 (risankizumab) in adult patients with AS, in order to provide
clinical proof of concept and to select dose (s) for confirmatory clinical trials.